Agomab Therapeutics

AGMBNasdaq Belgium Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$714.096 M

$14.50 +7.41%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

34,167,168

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#56DBV TechnologiesDBVT$798.2M
#57Candel TherapeuticsCADL$775.9M
#58Agomab TherapeuticsAGMB$714.1M
#59Allogene TherapeuticsALLO$693.8M
#60Tectonic TherapeuticTECX$584.6M

Where these numbers come from

Share counts and financials for Agomab Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.